Oruka Therapeutics, Inc. (ORKA): who owns it and who trades it
As of Nov 16, 2026, ORKA insiders reported 145 open-market sales worth $344M and no purchases in the last 12 months, with 12% of the sale value made under pre-set 10b5-1 plans. The largest seller was Tomas Kiselak (Director), with $300M. 5 of the 50 famous funds we follow held it at their last quarter end.
Latest filing Nov 16, 2026. From Form 4, 13F and Schedule 13D/G filings.
At a glance
Who is buying and selling Oruka Therapeutics
From the latest filingsOverall: about as much buying as selling. Insiders mostly sold. Funds and famous investors mostly bought.
Each group counts equally in the meter, by the number of buyers and sellers, not dollars. Insider sales under pre-set 10b5-1 plans are left out of it. From SEC, House and Senate filings; not advice.
Who owns ORKA
256 funds and institutions reported ORKA shares worth $7.1B at the end of Q2 2026. Some shares are counted by more than one filer, or lent out and counted twice, so the total can pass 100%. The largest holder is FMR LLC (Fidelity) with 15.0%.
Funds and institutions (13F) about 100%Everyone else 0%
10 largest owners, by share of the company
Top 20 owners
| Owner | Shares | % of company | Value | Change since Q1 2026 |
|---|---|---|---|---|
| FMR LLC (Fidelity) | 9.06M | 15.02% | $862M | +22% |
| BlackRock, Inc. | 4.99M | 8.27% | $475M | +41% |
| Venrock Adviser, LLC | 4.15M | 6.88% | $395M | No change |
| Fairmount Funds Management LLC | 3.71M | 6.14% | $353M | No change |
| Capital World Investors | 3.40M | 5.64% | $324M | – |
| Rtw Investments, LP | 3.14M | 5.20% | $299M | +53% |
| State Street Corp | 2.67M | 4.43% | $254M | +66% |
| Vanguard Capital Management LLC | 2.36M | 3.91% | $225M | +27% |
| Paradigm Biocapital Advisors LP | 2.14M | 3.56% | $204M | -8% |
| Deep Track Capital, LP | 1.93M | 3.19% | $183M | -5% |
| Bellevue Group AG | 1.66M | 2.75% | $158M | +227% |
| Franklin Resources Inc | 1.62M | 2.69% | $154M | +61% |
| Remedium Capital Partners, LLC | 1.57M | 2.60% | $149M | No change |
| Ra Capital Management, L.P. | 1.55M | 2.58% | $148M | – |
| Viking Global Investors LP | 1.50M | 2.49% | $143M | -44% |
| Geode Capital Management, LLC | 1.43M | 2.37% | $136M | +50% |
| Jupiter Topco LLC | 1.38M | 2.28% | $131M | – |
| Perceptive Advisors LLC | 1.35M | 2.23% | $128M | -4% |
| Polar Capital Holdings Plc | 1.23M | 2.04% | $117M | +17% |
| Citadel Advisors LLC | 1.12M | 1.86% | $106M | +11% |
From the SEC 13F data sets: every fund manager with over $100M must report its US stock holdings every 3 months, up to 45 days after the quarter ends. Owners are shown as they file, so one group (for example Vanguard) can appear under several names. Individuals, most insiders and smaller funds do not file 13F reports.
Insider trades
In the last 12 months, ORKA insiders reported $0 of open-market purchases and $344M of sales. 12% of the sale value was under a 10b5-1 plan, a schedule set up in advance.
Purchases and sales by month
Latest trades
| Date | Insider | Role | Type | Shares | Price | Value | Filing |
|---|---|---|---|---|---|---|---|
| Nov 16, 2026 | Joana Goncalves | Chief Medical Officer | Sale plan | 2,600 | $99.52 | $259K | Form 4 |
| Nov 16, 2026 | Joana Goncalves | Chief Medical Officer | Sale plan | 1,500 | $100.48 | $151K | Form 4 |
| Nov 16, 2026 | Joana Goncalves | Chief Medical Officer | Sale plan | 1,900 | $101.53 | $193K | Form 4 |
| Nov 16, 2026 | Joana Goncalves | Chief Medical Officer | Sale plan | 300 | $102.47 | $30.7K | Form 4 |
| Nov 16, 2026 | Joana Goncalves | Chief Medical Officer | Sale plan | 200 | $103.36 | $20.7K | Form 4 |
| Nov 16, 2026 | Joana Goncalves | Chief Medical Officer | Sale plan | 500 | $105.86 | $52.9K | Form 4 |
| Nov 12, 2026 | Arjun Agarwal | Vice president | Sale plan | 500 | $101.98 | $51K | Form 4 |
| Nov 12, 2026 | Arjun Agarwal | Vice president | Sale plan | 801 | $103.16 | $82.6K | Form 4 |
| Nov 12, 2026 | Arjun Agarwal | Vice president | Sale plan | 799 | $104.25 | $83.3K | Form 4 |
| Nov 12, 2026 | Arjun Agarwal | Vice president | Sale plan | 6,842 | $105.28 | $720K | Form 4 |
| Nov 12, 2026 | Arjun Agarwal | Vice president | Sale plan | 958 | $106.18 | $102K | Form 4 |
| Nov 12, 2026 | Arjun Agarwal | Vice president | Sale plan | 100 | $107.00 | $10.7K | Form 4 |
| Nov 12, 2026 | Kristine M Ball | Director | Sale plan | 1,196 | $102.10 | $122K | Form 4 |
| Nov 12, 2026 | Kristine M Ball | Director | Sale plan | 1,300 | $103.09 | $134K | Form 4 |
| Nov 12, 2026 | Kristine M Ball | Director | Sale plan | 2,039 | $104.16 | $212K | Form 4 |
| Nov 12, 2026 | Kristine M Ball | Director | Sale plan | 10,765 | $105.31 | $1.1M | Form 4 |
| Nov 12, 2026 | Kristine M Ball | Director | Sale plan | 2,500 | $106.05 | $265K | Form 4 |
| Nov 12, 2026 | Kristine M Ball | Director | Sale plan | 200 | $106.98 | $21.4K | Form 4 |
| Nov 2, 2026 | Lawrence Otto Klein | CEO | Sale plan | 6,466 | $94.77 | $613K | Form 4 |
| Nov 2, 2026 | Lawrence Otto Klein | CEO | Sale plan | 15,036 | $95.64 | $1.4M | Form 4 |
| Nov 2, 2026 | Lawrence Otto Klein | CEO | Sale plan | 2,442 | $96.70 | $236K | Form 4 |
| Nov 2, 2026 | Lawrence Otto Klein | CEO | Sale plan | 756 | $97.45 | $73.7K | Form 4 |
| Nov 2, 2026 | Lawrence Otto Klein | CEO | Sale plan | 300 | $98.40 | $29.5K | Form 4 |
| Oct 20, 2026 | Paul T Quinlan | General Counsel | Sale plan | 400 | $74.90 | $30K | Form 4 |
| Oct 20, 2026 | Paul T Quinlan | General Counsel | Sale plan | 500 | $76.12 | $38.1K | Form 4 |
| Oct 20, 2026 | Paul T Quinlan | General Counsel | Sale plan | 1,000 | $77.20 | $77.2K | Form 4 |
| Oct 20, 2026 | Paul T Quinlan | General Counsel | Sale plan | 4,100 | $78.79 | $323K | Form 4 |
| Oct 20, 2026 | Paul T Quinlan | General Counsel | Sale plan | 3,000 | $79.49 | $238K | Form 4 |
| Oct 15, 2026 | Joana Goncalves | Chief Medical Officer | Sale plan | 2,853 | $73.89 | $211K | Form 4 |
| Oct 15, 2026 | Joana Goncalves | Chief Medical Officer | Sale plan | 1,847 | $74.69 | $138K | Form 4 |
| Oct 15, 2026 | Joana Goncalves | Chief Medical Officer | Sale plan | 1,400 | $75.48 | $106K | Form 4 |
| Oct 15, 2026 | Joana Goncalves | Chief Medical Officer | Sale plan | 700 | $76.67 | $53.7K | Form 4 |
| Oct 15, 2026 | Joana Goncalves | Chief Medical Officer | Sale plan | 200 | $77.71 | $15.5K | Form 4 |
| Oct 12, 2026 | Arjun Agarwal | Vice president | Sale plan | 5,741 | $80.03 | $459K | Form 4 |
| Oct 12, 2026 | Arjun Agarwal | Vice president | Sale plan | 2,100 | $80.76 | $170K | Form 4 |
| Oct 12, 2026 | Arjun Agarwal | Vice president | Sale plan | 1,958 | $81.86 | $160K | Form 4 |
| Oct 12, 2026 | Arjun Agarwal | Vice president | Sale plan | 200 | $82.83 | $16.6K | Form 4 |
| Oct 1, 2026 | Lawrence Otto Klein | CEO | Sale plan | 16,246 | $83.40 | $1.4M | Form 4 |
| Oct 1, 2026 | Lawrence Otto Klein | CEO | Sale plan | 8,554 | $84.03 | $719K | Form 4 |
| Oct 1, 2026 | Lawrence Otto Klein | CEO | Sale plan | 200 | $84.78 | $17K | Form 4 |
| Sep 21, 2026 | Arjun Agarwal | Vice president | Sale plan | 533 | $95.75 | $51K | Form 4 |
| Sep 21, 2026 | Paul T Quinlan | General Counsel | Sale plan | 2,900 | $92.37 | $268K | Form 4 |
| Sep 21, 2026 | Paul T Quinlan | General Counsel | Sale plan | 2,667 | $95.31 | $254K | Form 4 |
| Sep 21, 2026 | Paul T Quinlan | General Counsel | Sale plan | 601 | $94.44 | $56.8K | Form 4 |
| Sep 21, 2026 | Paul T Quinlan | General Counsel | Sale plan | 3,832 | $93.32 | $358K | Form 4 |
| Sep 15, 2026 | Joana Goncalves | Chief Medical Officer | Sale plan | 947 | $95.71 | $90.6K | Form 4 |
| Sep 15, 2026 | Joana Goncalves | Chief Medical Officer | Sale plan | 1,366 | $92.99 | $127K | Form 4 |
| Sep 15, 2026 | Joana Goncalves | Chief Medical Officer | Sale plan | 3,150 | $92.03 | $290K | Form 4 |
| Sep 15, 2026 | Joana Goncalves | Chief Medical Officer | Sale plan | 2,384 | $91.10 | $217K | Form 4 |
| Sep 15, 2026 | Joana Goncalves | Chief Medical Officer | Sale plan | 100 | $94.22 | $9.4K | Form 4 |
| Sep 15, 2026 | Arjun Agarwal | Vice president | Sale plan | 560 | $95.71 | $53.6K | Form 4 |
| Sep 15, 2026 | Lawrence Otto Klein | CEO | Sale | 2,452 | $95.71 | $235K | Form 4 |
| Sep 15, 2026 | Paul T Quinlan | General Counsel | Sale | 1,039 | $95.71 | $99.4K | Form 4 |
| Sep 15, 2026 | Laura Lee Sandler | Chief Operating Officer | Sale | 906 | $95.71 | $86.7K | Form 4 |
| Sep 11, 2026 | Arjun Agarwal | Vice president | Sale plan | 3,000 | $91.11 | $273K | Form 4 |
| Sep 11, 2026 | Arjun Agarwal | Vice president | Sale plan | 4,051 | $92.41 | $374K | Form 4 |
| Sep 11, 2026 | Arjun Agarwal | Vice president | Sale plan | 2,208 | $93.26 | $206K | Form 4 |
| Sep 11, 2026 | Arjun Agarwal | Vice president | Sale plan | 200 | $94.02 | $18.8K | Form 4 |
| Sep 1, 2026 | Laura Lee Sandler | Chief Operating Officer | Sale plan | 4,000 | $92.01 | $368K | Form 4 |
| Sep 1, 2026 | Laura Lee Sandler | Chief Operating Officer | Sale plan | 1,000 | $91.05 | $91K | Form 4 |
| Sep 1, 2026 | Lawrence Otto Klein | CEO | Sale plan | 4,800 | $92.44 | $444K | Form 4 |
| Sep 1, 2026 | Lawrence Otto Klein | CEO | Sale plan | 63,596 | $91.90 | $5.8M | Form 4 |
| Sep 1, 2026 | Lawrence Otto Klein | CEO | Sale plan | 6,604 | $90.79 | $600K | Form 4 |
| Aug 17, 2026 | Joana Goncalves | Chief Medical Officer | Sale plan | 300 | $110.52 | $33.2K | Form 4 |
| Aug 17, 2026 | Joana Goncalves | Chief Medical Officer | Sale plan | 900 | $109.65 | $98.7K | Form 4 |
| Aug 17, 2026 | Joana Goncalves | Chief Medical Officer | Sale plan | 2,480 | $112.56 | $279K | Form 4 |
| Aug 17, 2026 | Joana Goncalves | Chief Medical Officer | Sale plan | 3,320 | $112.01 | $372K | Form 4 |
| Aug 14, 2026 | Paul T Quinlan | General Counsel | Sale plan | 3,847 | $111.14 | $428K | Form 4 |
| Aug 14, 2026 | Paul T Quinlan | General Counsel | Sale plan | 9,193 | $110.00 | $1M | Form 4 |
| Aug 14, 2026 | Paul T Quinlan | General Counsel | Sale plan | 10,200 | $109.11 | $1.1M | Form 4 |
| Aug 14, 2026 | Paul T Quinlan | General Counsel | Sale plan | 14,696 | $107.97 | $1.6M | Form 4 |
| Aug 14, 2026 | Paul T Quinlan | General Counsel | Sale plan | 10,434 | $107.14 | $1.1M | Form 4 |
| Aug 14, 2026 | Paul T Quinlan | General Counsel | Sale plan | 3,630 | $106.05 | $385K | Form 4 |
| Aug 13, 2026 | Arjun Agarwal | Vice president | Sale plan | 2,100 | $104.67 | $220K | Form 4 |
| Aug 13, 2026 | Arjun Agarwal | Vice president | Sale plan | 2,358 | $108.46 | $256K | Form 4 |
| Aug 13, 2026 | Arjun Agarwal | Vice president | Sale plan | 2,142 | $107.71 | $231K | Form 4 |
| Aug 13, 2026 | Arjun Agarwal | Vice president | Sale plan | 2,132 | $105.57 | $225K | Form 4 |
| Aug 13, 2026 | Arjun Agarwal | Vice president | Sale plan | 1,268 | $106.63 | $135K | Form 4 |
| Jul 15, 2026 | Joana Goncalves | Chief Medical Officer | Sale plan | 300 | $87.25 | $26.2K | Form 4 |
| Jul 15, 2026 | Joana Goncalves | Chief Medical Officer | Sale plan | 400 | $84.37 | $33.7K | Form 4 |
| Jul 15, 2026 | Joana Goncalves | Chief Medical Officer | Sale plan | 2,497 | $85.86 | $214K | Form 4 |
| Jul 15, 2026 | Joana Goncalves | Chief Medical Officer | Sale plan | 3,803 | $86.68 | $330K | Form 4 |
| Jul 13, 2026 | Arjun Agarwal | Vice president | Sale plan | 300 | $85.63 | $25.7K | Form 4 |
| Jul 13, 2026 | Arjun Agarwal | Vice president | Sale plan | 3,743 | $84.26 | $315K | Form 4 |
| Jul 13, 2026 | Arjun Agarwal | Vice president | Sale plan | 5,656 | $84.90 | $480K | Form 4 |
| Jul 13, 2026 | Arjun Agarwal | Vice president | Sale plan | 300 | $83.07 | $24.9K | Form 4 |
| Jul 1, 2026 | Tomas Kiselak +4 | Director | Sale | 3.55M | $84.43 | $300M | Form 4 |
| Jul 1, 2026 | Laura Lee Sandler | Chief Operating Officer | Sale plan | 500 | $95.47 | $47.7K | Form 4 |
| Jul 1, 2026 | Laura Lee Sandler | Chief Operating Officer | Sale plan | 2,263 | $94.75 | $214K | Form 4 |
| Jul 1, 2026 | Laura Lee Sandler | Chief Operating Officer | Sale plan | 2,237 | $93.85 | $210K | Form 4 |
| Jun 22, 2026 | Arjun Agarwal | Vice president | Sale plan | 888 | $80.01 | $71K | Form 4 |
| Jun 22, 2026 | Arjun Agarwal | Vice president | Sale plan | 699 | $82.15 | $57.4K | Form 4 |
| Jun 15, 2026 | Arjun Agarwal | Vice president | Sale plan | 395 | $69.69 | $27.5K | Form 4 |
| Jun 15, 2026 | Joana Goncalves | Chief Medical Officer | Sale plan | 947 | $69.69 | $66K | Form 4 |
| Jun 15, 2026 | Joana Goncalves | Chief Medical Officer | Sale plan | 5,064 | $69.42 | $352K | Form 4 |
| Jun 15, 2026 | Joana Goncalves | Chief Medical Officer | Sale plan | 300 | $70.62 | $21.2K | Form 4 |
| Jun 15, 2026 | Joana Goncalves | Chief Medical Officer | Sale plan | 1,636 | $68.38 | $112K | Form 4 |
| Jun 15, 2026 | Lawrence Otto Klein | CEO | Sale | 1,729 | $69.69 | $120K | Form 4 |
| Jun 15, 2026 | Laura Lee Sandler | Chief Operating Officer | Sale | 600 | $69.69 | $41.8K | Form 4 |
| Jun 15, 2026 | Paul T Quinlan | General Counsel | Sale | 733 | $69.69 | $51.1K | Form 4 |
Latest 100 of 145 trades in the last 12 months.
Insiders by value traded
| Insider | Role | Bought | Sold | Last trade |
|---|---|---|---|---|
| Tomas Kiselak | Director, 10% owner | – | $300M | Jul 1, 2026 |
| Lawrence Otto Klein | Chief Executive Officer, Director | – | $11.8M | Nov 2, 2026 |
| Carl Dambkowski | Director | – | $8.6M | Jun 12, 2026 |
| Paul T Quinlan | General Counsel | – | $7.5M | Oct 20, 2026 |
| Arjun Agarwal | Senior Vice President, Finance | – | $6.2M | Nov 12, 2026 |
| Joana Goncalves | Chief Medical Officer | – | $5.8M | Nov 16, 2026 |
| Laura Lee Sandler | Chief Operating Officer | – | $1.9M | Sep 15, 2026 |
| Kristine M Ball | Director | – | $1.9M | Nov 12, 2026 |
What this data shows, and what it doesn't
- Shows: open-market purchases and sales by officers, directors and 10%+ owners, reported on Form 4 within two business days of the trade.
- Leaves out: stock awards, option exercises, shares withheld for tax and gifts. These are not trades at a market price chosen by the insider.
- "plan" marks a sale made under a Rule 10b5-1 plan, a schedule set up in advance.
- Fund holders come from 13F reports, a snapshot at quarter end filed up to 45 days later.
- Filings are self-reported and can be amended. Each trade links to its original filing. Methodology
ORKA short interest
Moderate short interest. 9.8% of ORKA shares are sold short: about 1 share in 10. Over the last 12 reports the number of shares short went up 3%.
As a rough guide, under 5% is low, 5–10% is moderate, 10–20% is high and over 20% is very high.
As of Oct 30, 2026, 6.46M ORKA shares were sold short, 9.8% of the shares outstanding, up 5.8% from the report before. At the average daily volume of 915,065 shares, buying them all back would take about 7.1 trading days (days to cover).
Shares short, % of all shares
Days to cover
Every report
| Settlement date | Shares short | % of shares | Change | Avg daily volume | Days to cover |
|---|---|---|---|---|---|
| Oct 30, 2026 | 6.46M | 9.76% | +6% | 915,065 | 7.1 |
| Oct 15, 2026 | 6.11M | 9.23% | -21% | 841,406 | 7.3 |
| Sep 30, 2026 | 7.78M | 11.75% | +2% | 1.23M | 6.3 |
| Sep 15, 2026 | 7.62M | 11.51% | -2% | 656,686 | 11.6 |
| Aug 31, 2026 | 7.79M | 11.77% | -6% | 840,475 | 9.3 |
| Aug 14, 2026 | 8.30M | 12.54% | +3% | 732,736 | 11.3 |
| Jul 31, 2026 | 8.05M | 12.16% | -9% | 961,164 | 8.4 |
| Jul 15, 2026 | 8.83M | 14.65% | -4% | 1.42M | 6.2 |
| Jun 30, 2026 | 9.16M | 15.19% | +33% | 2.14M | 4.3 |
| Jun 15, 2026 | 6.90M | 11.44% | +8% | 1.13M | 6.1 |
| May 29, 2026 | 6.37M | 10.57% | +2% | 1.28M | 5.0 |
| May 15, 2026 | 6.25M | 10.37% | -11% | 1.75M | 3.6 |
Short sellers borrow shares and sell them, hoping to buy them back for less. A high number means many such bets are open. It does not say where the price will go. Source: FINRA equity short interest, reported by brokers twice a month (positions on the 15th and the last business day) and published about 7 business days later. % of shares uses the share count on the company's latest SEC filing. What short interest means · Most shorted stocks
Oruka Therapeutics company events
Oruka Therapeutics filed 8 reports on Form 8-K in the last 12 months, 2 of them about an important change (leadership). The latest was on Oct 26, 2026.
- Oct 26, 2026AnnouncementOruka announced Week 16 results from its Phase 2b EVERLAST-B clinical trial of ORKA-001 in patients with moderate-to-severe PsO. EVERLAST-B Phase 2b Key 16-Week Results EVERLAST-B is a randomized, double-blind, placebo-controlled Phase 2b clinical trial evaluating the safety, efficacy and… Filing
- Aug 24, 2026LeadershipOruka Therapeutics, Inc. entered into a letter agreement with Todd Edwards pursuant to which Mr. Edwards commenced employment as Chief Commercial Officer on August 24, 2026. Filing
- Aug 10, 2026ResultsReleased financial results. Filing
- Jun 4, 2026VoteReported shareholder vote results. Filing
- Jun 1, 2026AnnouncementOruka Therapeutics, Inc. entered into the First Amendment to IL-23 License Agreement, amending the IL-23 License Agreement dated as of December 17, 2024, by and between the Company and Paragon Therapeutics, Inc. Filing
- Apr 30, 2026AnnouncementThe Company entered into an Underwriting Agreement with Leerink Partners LLC, TD Securities (USA) LLC, Goldman Sachs & Co. LLC, Stifel, Nicolaus & Company, Incorporated and Guggenheim Securities, LLC, as the representatives of the several underwriters named in Schedule A thereto, providing for the… Filing
- Apr 27, 2026AnnouncementOruka announced results from its Phase 2a EVERLAST-A clinical trial of ORKA-001 in patients with moderate-to-severe PsO. EVERLAST-A Phase 2a Key 16-Week Results The Phase 2a EVERLAST-A clinical trial is a randomized, double-blind, placebo-controlled study evaluating ORKA-001 in patients with… Filing
- Dec 11, 2025LeadershipCameron Turtle resigned as a member of the Board of Directors of Oruka Therapeutics, Inc. Filing
From 8-K reports, which a company must file within 4 business days of an important event. Where a report is about a change such as a new CEO, the sentence is the first one from the report itself, shortened. Each row links to the original filing. Company events this week
Oruka Therapeutics financials
Famous investors that hold ORKA
5 of the 50 well-known investors we track reported holding ORKA in their latest 13F filing. The largest position is Steve Cohen's, worth $31.1M.
Position size
All holders
| Fund | Quarter | Shares | Value | Of portfolio | Change |
|---|---|---|---|---|---|
| Steve Cohen · Point72 Asset Management | Q3 2026 | 373,455 | $31.1M | 0.1% | New |
| Ken Fisher · Fisher Asset Management | Q3 2026 | 215,593 | $18M | 0.0% | +218% |
| Israel Englander · Millennium Management | Q3 2026 | 158,558 | $13.2M | 0.0% | +382% |
| Andreas Halvorsen · Viking Global Investors | Q3 2026 | 58,000 | $4.8M | 0.0% | -96% |
| Ken Griffin · Citadel Advisors | Q3 2026 | 5,528 | $460K | 0.0% | -100% |
From 13F reports: a snapshot at quarter end, filed up to 45 days later. Change compares with the quarter before.
5%+ stakes filed in the last 120 days
Anyone who owns more than 5% of a company must report it on Schedule 13D or 13G. 4 filings named ORKA in the last 120 days.
| Filed | Holder | Form | Stake |
|---|---|---|---|
| Nov 16, 2026 | T. Rowe Price Investment Management, Inc. | 13G | 6.6% |
| Nov 16, 2026 | T. Rowe Price Investment Management, Inc. | 13G | 6.6% |
| Nov 16, 2026 | RTW Investments, LP | 13G/A | 4.7% |
| Nov 16, 2026 | RTW Investments, LP | 13G/A | 4.7% |
Questions about Oruka Therapeutics, Inc. (ORKA) stock
Who owns the most ORKA stock?
The largest reported owner of Oruka Therapeutics, Inc. (ORKA) is FMR LLC (Fidelity), with 15.0% of the company. In total, 256 funds and institutions reported holding ORKA at the end of Q2 2026, together about 100% of the shares. See the largest owners.
Are ORKA insiders buying or selling?
In the last 12 months, ORKA insiders reported no open-market purchases and 145 sales worth $344M. The latest trade was on Nov 16, 2026. See every trade.
What is the short interest in ORKA?
As of Oct 30, 2026, 6.46M ORKA shares were sold short, 9.8% of the shares outstanding, up 5.8% from the report before. At the average daily volume of 915,065 shares, buying them all back would take about 7.1 trading days (days to cover). See the history.
Which famous investors hold ORKA?
5 of the 50 well-known investors we track reported ORKA in their latest 13F filing, including Steve Cohen, Ken Fisher, Israel Englander. The largest position is worth $31.1M. See all holders.
Source: SEC Form 4 (insiders, filed within 2 business days), 13F (funds, up to 45 days after quarter end) and Schedule 13D/13G filings. Only open-market purchases (code P) and sales (code S) are shown. Data only, not investment advice. How we collect it.